Research graph
References from Beyond endothelial cells: mutant p53 drives de novo von Willebrand factor expression. Local targets link to admitted publications; unresolved targets remain external evidence.
von Willebrand factor clearance - biological mechanisms and clinical significance
10.1111/bjh.15565 · 2018 · External reference
von Willebrand factor expression in osteosarcoma metastasis
10.1038/modpathol.3800265 · 2005 · External reference
The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study
10.1016/j.jprot.2014.04.021 · 2014 · External reference
Functional assessment of von Willebrand factor expression by cancer cells of non-endothelial origin
10.18632/oncotarget.14273 · 2017 · External reference
Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma
10.1038/s41389-017-0023-5 · 2018 · External reference
The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
10.1016/j.jtha.2026.07.005 · 2026 · External reference
Differential effect of plakoglobin in restoring the tumor suppressor activities of p53-R273H vs. p53-R175H mutants
10.1371/journal.pone.0306705 · 2024 · External reference
Aging is associated with organ-specific alterations in the level and expression pattern of von Willebrand factor
10.1161/atvbaha.123.319255 · 2023 · External reference
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells
10.1182/blood-2004-06-2272 · 2005 · External reference
Contribution of platelets to tumour metastasis
10.1038/nrc3004 · 2011 · External reference
Von Willebrand factor and cancer; metastasis and coagulopathies
10.1111/jth.14976 · 2020 · External reference
Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration
10.1111/jth.15794 · 2022 · External reference
Development and validation of a predictive model for chemotherapy- associated thrombosis
10.1182/blood-2007-10-116327 · 2008 · External reference
Cancer genetic alterations and risk of venous thromboembolism
10.1016/j.thromres.2021.12.008 · 2022 · External reference
Impact of tumor genomic mutations on thrombotic risk in cancer patients
10.3390/cancers12071958 · 2020 · External reference
Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer
10.1111/jth.12910 · 2015 · External reference
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
10.1111/jth.14129 · 2018 · External reference
Mechanisms of cancer-associated thrombosis
10.1016/j.rpth.2023.100123 · 2023 · External reference
Associations of tumor somatic mutations with cancer-associated venous thromboembolism
10.1016/j.jtha.2026.01.019 · 2026 · External reference
The epithelial-mesenchymal plasticity landscape: principles of design and mechanisms of regulation
10.1038/s41576-023-00601-0 · 2023 · External reference
